Sera Prognostics (SERA) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Sera Prognostics (SERA) is set to announce its Q2 2025 earnings on August 6th, with analysts expecting an earnings per share of ($0.21) and revenue of $0.05 million.
• The company's CEO, Zhenya Lindgardt, sold 23,042 shares for approximately $32,950, which represents a 2.66% decrease in their holdings, and insiders have sold a total of 67,848 shares in the last ninety days.
• Wall Street analysts have upgraded Sera Prognostics from a "sell" rating to a "hold" rating, indicating a cautious optimism about the company's future performance.

Sera Prognostics (NASDAQ:SERA - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.05 million for the quarter.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Sera Prognostics had a negative net margin of 28,685.22% and a negative return on equity of 51.35%. The company had revenue of $0.04 million during the quarter, compared to analysts' expectations of $0.06 million. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Down 2.9%

SERA stock traded down $0.08 during mid-day trading on Friday, reaching $2.70. 59,613 shares of the stock traded hands, compared to its average volume of 118,313. Sera Prognostics has a 52 week low of $1.37 and a 52 week high of $9.13. The business has a 50-day moving average of $2.32 and a two-hundred day moving average of $3.36. The firm has a market capitalization of $101.71 million, a PE ratio of -2.87 and a beta of 0.99.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Sera Prognostics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st.

Insider Buying and Selling at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 23,042 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $1.43, for a total value of $32,950.06. Following the completion of the sale, the chief executive officer owned 844,209 shares in the company, valued at approximately $1,207,218.87. This trade represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 67,848 shares of company stock valued at $128,049 in the last three months. 13.50% of the stock is currently owned by company insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.